GBT 440-032 A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE Kids 2)

Project: Research project

Project Details

StatusActive
Effective start/end date7/25/187/24/23

Funding

  • Global Blood Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.